The severity of obstructive sleep apnea (OSA) is known to be reduced by a combination of noradrenergic agents like reboxetine and antimuscarinic agents like oxybutynin. Recently, an RCT evaluated what works better – reboxetine alone or in combination with oxybutynin – against the severity of OSA in 16 OSA patients . What did they find? Reboxetine (4 mg) alone decreased the apnea-hypopnea index (AHI) by 5.4 events/h.
The addition of oxybutynin (5 mg) to reboxetine treatment didn’t further reduce the AHI. Reboxetine decreased the 4% oxygen desaturation index by 5.2 ± 7.2 events/h, while reboxetine+oxybutynin decreased it by 5.1 ± 10.6 events/h compared to placebo. Reboxetine increased nadir oxygen saturation by 7 ± 11%, while reboxetine+oxybutynin increased it by 5 ± 9% compared to placebo. However, both reboxetine alone and reboxetine+oxybutynin treatments improved pharyngeal…
